These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2751261)

  • 1. Effect of the tiapamil analog RO11-2933 on cellular sensitivity to antitumor drugs in sensitive and multidrug resistant human ovarian cancer cells.
    Mazzoni A; Trave F; Canti G; Franco P
    Anticancer Res; 1989; 9(2):367-71. PubMed ID: 2751261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
    Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
    Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells.
    Mazzoni A; Trave F
    Oncol Res; 1993; 5(2):75-82. PubMed ID: 8364256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933.
    Alaoui-Jamali MA; Schecter RL; Rustum YM; Centurioni MG; Lehnert S; Batist G
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1299-304. PubMed ID: 8450465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells.
    Mazzoni A; Trave F; Fabbri M; Leto G; Ghidoni R
    Anticancer Res; 1991; 11(6):2181-5. PubMed ID: 1776860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents.
    Berger B; Marquardt H; Westendorf J
    Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
    Yin MB; Bankusli I; Rustum YM
    Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
    Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
    Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
    Plumb JA; Wishart GC; Setanoians A; Morrison JG; Hamilton T; Bicknell SR; Kaye SB
    Biochem Pharmacol; 1994 Jan; 47(2):257-66. PubMed ID: 8304970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
    Stefańska B; Dzieduszycka M; Bontemps-Gracz MM; Borowski E; Martelli S; Supino R; Pratesi G; De Cesare M; Zunino F; Kuśnierczyk H; Radzikowski C
    J Med Chem; 1999 Sep; 42(18):3494-501. PubMed ID: 10479282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.